Navigation Links
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
Date:1/9/2012

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs), today announced that Eric K. Rowinsky, M.D. will join the Company as Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will oversee the development and registration efforts for the Company's two clinical stage drug candidates, SL-401 and SL-701, as well as its preclinical pipeline.

"I am very excited to join Stemline at such an important time for the Company," said Dr. Rowinsky. He continued, "Not only is the Company's clinical stage pipeline extremely unique compared to other therapeutics in development, but both SL-401 and SL-701 are demonstrating objective anti-tumor activity in several malignancies that represent important unmet medical needs. I look forward to developing these novel agents to their fullest potential, advancing Stemline's programs towards potential global registration, and, in doing so, hopefully improving the lives of people with a variety of malignancies."

Ivan Bergstein, Stemline's Chief Executive Officer, said, "Dr. Rowinsky brings a wealth of drug development experience to the Stemline team and we look forward to his contribution and leadership in advancing our pipeline forward."

Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs from preclinical to regulatory approval. Among his many endeavors before joining Stemline was that of Executive Vice President and Chief Medical Officer for Imclone Systems, Inc., where he led the FDA approval of Erbitux® for head and neck and colorectal cancers, and advanced eight other monoclonal antibodies through clinical development. Before joining Imclone, Dr. Rowinsky was the Director of the Institute of Drug Development ("IDD") at the Cancer Therapy and Research Center. In addition,
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... Oct. 30, 2014 Molecular Profiles Ltd., a ... ) and Maryland -based Xceleron have ... efficiency during clinical development that will be launched at ... week. This partnership extends Molecular Profiles, new ... launched earlier this month. The company also has complementary ...
(Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... April 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... calls focused on the drugs in Isis, development pipeline.  The second call of ... Wednesday, April 28, 2010 at 12:00 p.m. ET .  This ... , , ...
... , TITUSVILLE, N.J. , April 26 The Court ... Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision ... for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed ... , In ...
Cached Medicine Technology:Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3CONCERTA(R) Patent Appeal Denied 2CONCERTA(R) Patent Appeal Denied 3
(Date:10/30/2014)... October 30, 2014 Paramount Rx, a ... is increasing efforts to help people save money through ... to increase for prescription drugs in the new health ... and resources to bridge the relationship between consumers, businesses ... the biggest challenges people face today with medical costs ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... IL (PRWEB) October 30, 2014 Dr. Joseph ... a new website for his practices; OB GYN in ... IL . This website contains important information about each ... as well as downloadable patient forms in English and Spanish. ... and the service pages on the website provide Dr. Furlin’s ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... that men who have undergone vasectomy may be at ... study was published in Cognitive and Behavioural Neurology. ... of this, 25 developed a dementia called primary progressive ... the chief scientist of this study Sandra Weintraub, this ...
... have multiple sclerosis (MS) for 10 years and have few of ... “benign MS” and that their symptoms will likely not ever occur ... study shows that unfortunately this may not be correct. ... of those whose MS was benign at 10 years, according to ...
... test that can distinguish between a pair of nearly ... treatment. ,Their report is published this week ... the National Academy of Sciences. ,"This simple ... quickly implemented in the clinic to benefit patients by ...
... appreciable decline in the number of women dying at childbirth ... Gautemala and Morocco that have managed to arrest this trend. ... of maternal deaths per 100,000 live births, was 301 in ... 70,000 women die every year in India but UNICEF says ...
... An anti-smoking campaign in Colorado that involves door-to-door ... of thousands of dollars and "is raising questions ... cessation efforts among minorities, the Denver Rocky Mountain ... approved a tobacco tax increase, which so far ...
... a national study, patients being treated for a ... Shore University Hospital// (NSUH) and Long Island Jewish ... arsenic compound, coupled with standard chemotherapy treatments, significantly ... newly-diagnosed acute promyelocytic leukemia, or APL, and participated ...
Cached Medicine News:Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2Health News:India Lags Far Behind in Controlling Maternal Deaths 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3
... to Z Drug Facts produced by ... on thousands of medications. It provides ... effect, drug interactions, patient information and ... reference for physicians, students, residents, pharmacists, ...
Very concise book answering the question: "I've got a diagnosis, which drugs do I use?". All 15 chapters written by highly skilled US specialists...
... with Integrated Calculators, based on Davis's Drug ... advance in drug reference. DDGNIC contains the ... Guide (9th Edition) and has integrated calculation ... product merges many of the advantages of ...
Allows health professionals to answer consumers' questions regarding safety issues concerning possible drug-herb and drug-food interactions....
Medicine Products: